Rivastigmine treatment as an add‑on to antipsychotics in patients with schizophrenia and cognitive deficits

References

• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004;351:2509–18
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer’s disease. Curr Pharm Des 2004;10:231–51
   PubMed Web of Science ®Google Scholar
• Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry 2006;21: 17–28
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, et al. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000;48:381–8
   PubMed Web of Science ®Google Scholar
• Holt DJ, Herman MM, Hyde TM, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999;94:21–31
   PubMed Web of Science ®Google Scholar
• Green MF. Schizophrenia from a neurocognitive perspective. Probing the impenetrable darkness. Boston: Allyn and Bacon, 1998
   Google Scholar
• Sharma T, Harvey P. Cognition in schizophrenia: impairments, importance, and treatment strategies. New York: Oxford University Press, 2000
   Google Scholar
• Rémillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a one-year followup study. Schizophr Res 2005;80: 99–106
   Google Scholar
• Lussier I, Stip E. Memory and attention deficits in drug naive patients with schizophrenia. Schizophr Res 2001;48:45–55
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D, Gasbarre L. Distractibility and symptoms in schizophrenia. J Psychiatr Neurosci 1997;22: 180–4
   PubMed Web of Science ®Google Scholar
• Chen WJ, Liu SK, Chang CJ, et al. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatr 1998;155: 1214–20
   PubMed Web of Science ®Google Scholar
• Hintze B, Kuhn-Dymecka A, Bembenek A, et al. Attention impairment in patients suffering from schizophrenia and their relatives of first-degree. Psychiatr Pol 2004;38:861–73
   PubMedGoogle Scholar
• Goldberg TE, Torrey EF, Gold JM, et al. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol Med 1993;23:71–85
   PubMed Web of Science ®Google Scholar
• Toulopoulouand T, Murray RM. Verbal memory deficit in patients with schizophrenia: an important future target for treatment. Expert Rev Neurother 2004;4:43–52
   PubMedGoogle Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426–45
   PubMed Web of Science ®Google Scholar
• Tollefson GD. Cognitive function in schizophrenic patients. J Clin Psychiatry 1996;57:31–9
   PubMed Web of Science ®Google Scholar
• McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45: 175–84
   PubMed Web of Science ®Google Scholar
• Semkovska M, Bedard M-A, Godbout L, et al. Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res 2004;69:289–300
   PubMed Web of Science ®Google Scholar
• Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301–7
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233–55
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian collaborative group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249–58
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457–72
   PubMed Web of Science ®Google Scholar
• Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for increased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22–33
   PubMed Web of Science ®Google Scholar
• Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr 2004;9:350–5
   Google Scholar
• Karson CN, Mrak RE, Hussain MM, et al. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Mol Chem Neuropathol 1996;29:181–91
   PubMedGoogle Scholar
• Hussain M, Chaudhry Z, Hussain S. Rivastigmine tartrate in treatment of neocognitive deficits in clozapine treated schizophrenics. 51st annual meeting of Canadian Psychiatric Association book of abstracts. CPA 2001, p.64
   Google Scholar
• Kirrane RM, Mitroupoulou V, Nunn M, et al. Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 2001;48:1–5
   PubMed Web of Science ®Google Scholar
• MacEwan GW, Ehmann TS, Khanbhai I, et al. Donepezil in schizophrenia: is it helpful? An experimental design case study. Acta Psychiatr Scand 2001;104:469–72
   PubMed Web of Science ®Google Scholar
• Friedman JI, Adler DN, Howanitz E, et al. A double-blind placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002;5:349–57
   Google Scholar
• Reitstetter R, Lukas RJ, Gruener R. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 1999;289: 656–60
   Google Scholar
• Blaxton TA, Myers C, Kakoyannis A, et al. Effects of nicotine on memory in schizophrenic patients. Schizophr Res 2001; 49:127
   Web of Science ®Google Scholar
• Buchanan RW, Summerfelt A, Tek C, et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003;59: 29–33
   PubMed Web of Science ®Google Scholar
• Erickson SK, Schwarzkopf SB, Palumbo D, et al. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 2005;28:179–84
   PubMed Web of Science ®Google Scholar
• Lenzi A, Maltinti E, Poggi E, et al. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 2003;26:317–21
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005;181:358–63
   PubMed Web of Science ®Google Scholar
• Tugal O, Yazici KM, Anil Yagcioglu AE, et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004;7:117–23
   PubMed Web of Science ®Google Scholar
• Stip E, Sepehry AA, Chouinard S, et al. Add-on therapy with cholinesterase inhibitors for memory dysfunction in schizophrenia: a meta-analysis. [submitted to Clinical Neuropharmacology 2006]
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Washington DC: American Psychiatric Association, 1994
   Google Scholar
• Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663–7
   PubMed Web of Science ®Google Scholar
• Wilk CM, Gold JM, Humber K, et al. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res 2004;70:175–86
   PubMed Web of Science ®Google Scholar
• Kay SR, Casanova MF, Kleinman JE, et al. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry 1989;7:59–67
   Google Scholar
• Pantelis C, Barnes TRE, Nelson HE, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997;120:1823–43
   PubMed Web of Science ®Google Scholar
• Potvin S, Briand C, Prouteau A, et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn 2005;59:38–42
   PubMed Web of Science ®Google Scholar
• Prouteau A, Verdoux H, Briand C, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res 2005;77:343–53
   PubMed Web of Science ®Google Scholar
• Stip E, Sepehry AA, Prouteau A, et al. Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain Cogn 2005;59:292–5
   PubMed Web of Science ®Google Scholar
• Prouteau A, Verdoux H, Briand C, et al. Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res 2004;69:85–91
   PubMed Web of Science ®Google Scholar
• Stip E, Caron J, Lecomte Y, et al. A new scale to evaluate subjective cognition in schizophrenia: the SSTICS. Schizophr Res 2001;49:146
   Web of Science ®Google Scholar
• Pomerleau CS, Carton S-M, Lutzke ML, et al. Reliability of the Fagerstrom Tolerance Questionnaire and the Fagerstrom Test for Nicotine Dependence. Addict Behav 1994;19:33–9
   Google Scholar
• Sharma T, Reed C, Aasen I, et al. Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006;85:73–83
   PubMed Web of Science ®Google Scholar
• Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006;60:530–3
   Google Scholar
• Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006:88;63–72
   PubMed Web of Science ®Google Scholar
• Aesen I, Kumari V, Sharma T. Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. J Clin Psychopharmacol 2005;25:311–7
   Google Scholar